HS-20110 for Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new treatment called HS-20110 to assess its safety and tolerability in individuals with advanced solid tumors (cancer that has spread and formed solid lumps). Participants will receive HS-20110 to help researchers determine the optimal dose and identify any side effects. The trial seeks individuals diagnosed with advanced solid tumors who have at least one measurable tumor, excluding those in the brain. As a Phase 1 trial, the research focuses on understanding how the treatment works in people, offering participants the opportunity to be among the first to receive this new treatment.
Will I have to stop taking my current medications?
You may need to stop taking certain medications before joining the trial, especially if they are anti-tumor drugs, drugs affecting specific liver enzymes, or drugs that affect heart rhythm. The trial does not specify all medications, so it's best to discuss your current medications with the trial team.
Is there any evidence suggesting that HS-20110 is likely to be safe for humans?
Research shows that HS-20110 is still undergoing testing to determine its safety and tolerability, particularly in individuals with advanced solid tumors. This treatment is in the early testing phase, so researchers closely monitor participants to observe their responses. In Phase 1, the primary goal is to assess the treatment's safety for humans and identify any side effects.
Detailed safety information for HS-20110 remains limited because testing is ongoing. However, these early tests aim to identify potential risks and evaluate how well participants tolerate the treatment. Researchers closely monitor participants for any adverse reactions, which aids in understanding the treatment's safety.12345Why do researchers think this study treatment might be promising?
Researchers are excited about HS-20110 because it targets cancer in a novel way. Unlike standard treatments like chemotherapy and radiation, which attack both healthy and cancerous cells, HS-20110 is designed to specifically target cancer cells, potentially reducing side effects. This targeted approach could lead to more effective treatment outcomes and a better quality of life for patients. Additionally, HS-20110 may open new avenues for treating types of cancer that are resistant to current therapies.
What evidence suggests that HS-20110 might be an effective treatment for cancer?
Research has shown that HS-20110, the investigational treatment in this trial, has produced promising results in early tests for treating solid tumors, such as colorectal cancer. In initial studies, participants demonstrated noticeable improvements in tumor response. This treatment targets cancer cells to inhibit their growth and spread. Early findings suggest this method might help manage advanced solid tumors, but further information is needed to confirm these results.12346
Are You a Good Fit for This Trial?
This trial is for individuals with advanced solid tumors, including uterine tumors. Participants must have at least one measurable lesion that can be tracked for changes. They should have a confirmed diagnosis through pathology but cannot join if they have brain lesions or conditions not disclosed here.Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Dose Escalation
Participants receive escalating doses of HS-20110 to evaluate safety and tolerability
Dose Expansion
Participants receive the determined safe dose of HS-20110 to further evaluate efficacy
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- HS-20110
Find a Clinic Near You
Who Is Running the Clinical Trial?
Hansoh BioMedical R&D Company
Lead Sponsor